Welcome to our dedicated page for Vyant Bio news (Ticker: VYNT), a resource for investors and traders seeking the latest updates and insights on Vyant Bio stock.
Vyant Bio, Inc. (Nasdaq: VYNT) is a pioneering biotechnology company focused on transforming lives through the integration of human biology, engineering, and data science. Under the leadership of Andrew LaFrence, who serves as President, Chief Executive Officer, and Chief Financial Officer, Vyant Bio aims to revolutionize the biomedical field with innovative solutions.
Vyant Bio's core business involves leveraging cutting-edge technologies and a multidisciplinary approach to develop solutions that address critical medical needs. The company is dedicated to harnessing the power of data science and engineering to create more effective and personalized treatments.
Recent achievements include the development of state-of-the-art therapeutic platforms that utilize human biology to enhance drug discovery processes. These platforms are designed to improve the accuracy and efficiency of identifying viable drug candidates, thereby accelerating the pathway from research to clinical application.
Vyant Bio is currently involved in several key projects, including collaborations with leading pharmaceutical companies and academic institutions. These partnerships are aimed at expanding the scope and impact of their research and development efforts.
Financially, Vyant Bio is committed to maintaining a strong balance sheet and ensuring sustainable growth. The company continuously explores new opportunities for funding and strategic alliances to support its ambitious research initiatives.
For those seeking the latest updates and relevant information about Vyant Bio, the company's official website, www.vyantbio.com, offers comprehensive resources. Forward-looking statements and additional investor information can also be found on the website.
Reaction Biology has acquired Vyant Bio’s U.S. operations of vivoPharm for $5.5 million. This transaction enhances Reaction's drug discovery capabilities, integrating in vitro and in vivo services. Vyant Bio anticipates netting approximately $4.4 million after taxes and transaction expenses. The acquisition allows Vyant to focus resources on developing its therapeutic pipeline for genetic CNS disorders. The deal is seen as a strategic move, providing Reaction with additional laboratory facilities and expertise to support its clients in biopharmaceutical research.
Vyant Bio (Nasdaq: VYNT) has announced a 1-for-5 reverse stock split of its outstanding common stock, effective November 2, 2022. The move aims to boost the per-share trading price to meet the $1.00 minimum bid price requirement for continued listing on Nasdaq. Following the split, outstanding shares will decrease from approximately 29.4 million to around 5.9 million. Shareholders will receive cash for any fractional shares. The reverse split was approved by shareholders on July 14, 2022, with the board confirming the 1:5 ratio on October 23, 2022.
Vyant Bio (Nasdaq: VYNT) showcased its advanced drug discovery platform at the 2022 CDKL5 Forum in Boston on November 7-8, 2022. The company highlighted its unique approach that leverages human-derived organoid models and machine learning to develop therapies for CDKL5 deficiency disorder (CDD). During the forum, Vyant will give a platform presentation titled High-throughput functional screening to develop novel therapies for CDKL5-deficiency disorder, and participate in a workshop discussing best practices for using induced pluripotent stem cell-derived brain organoids.
Vyant Bio (Nasdaq: VYNT) has announced its participation in the LD Micro Main Event XV on October 26, 2022, showcasing its innovative drug discovery platform targeting neurodevelopmental and neurodegenerative disorders. The presentation by CEO Jay Roberts will cover significant scientific, business, and strategic milestones.
The event will take place at the Luxe Sunset Boulevard Hotel in Los Angeles, with Vyant management available for one-on-one meetings throughout the day. For more details and registration, visit the conference website.
Vyant Bio, Inc. (Nasdaq: VYNT) announced its participation in the Skyline Signature Series on September 8, 2022. This live, interactive online presentation will allow investors to engage with the company in real-time. Vyant Bio focuses on drug discovery for neurodevelopmental and neurodegenerative disorders utilizing a proprietary CNS platform that integrates human-derived organoid models and machine learning. Investors are required to pre-register for the event, which aims to facilitate effective communication with a curated audience of financial professionals.
Vyant Bio (Nasdaq: VYNT), a biotechnology company focused on drug discovery for neurodevelopmental and neurodegenerative disorders, has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. CEO Jay Roberts will discuss significant milestones during the presentation. Registered attendees can access the on-demand presentation starting on September 12 at 7:00 AM ET, available for 90 days until December 11, 2022. For more information, visit www.vyantbio.com.
Vyant Bio (Nasdaq: VYNT) announces progress on its CNS drug discovery platform, revealing plans to commence clinical trials for VYNT-0126 in Rett Syndrome patients, following promising preclinical efficacy data. Financially, as of June 30, 2022, the company holds $11.7 million in cash with a runway of approximately 18 months. Efforts to divest vivoPharm are ongoing, classified as a held-for-sale asset. The company reported a second-quarter loss of $4.3 million but a decrease in overall losses compared to the previous year. Upcoming conference call scheduled for August 22, 2022.
Vyant Bio (Nasdaq: VYNT), a biotech company focusing on drug discovery for neurodevelopmental and neurodegenerative disorders, will release its Q2 and first half 2022 financial results on August 22, 2022. An investor conference call will follow at 4:30 pm ET, featuring management updates on business, scientific, and financial progress. The company utilizes a proprietary CNS drug discovery platform that integrates organoid models and machine learning to enhance drug development efficiency. Investors can submit questions via email prior to the event.
Vyant Bio has postponed its Q2 and H1 2022 investor conference call due to recent developments affecting the valuation of its vivoPharm subsidiary. This change is attributed to accounting revisions related to tax considerations that may impact net sales and result in a non-cash intangible asset impairment charge. A new date for the earnings call will be announced after the completion of the valuation and tax analyses.
Vyant Bio focuses on drug discovery for neurodevelopmental and neurodegenerative disorders, integrating organoid models and machine learning technologies.
Vyant Bio (Nasdaq: VYNT), a biotechnology company focused on drug discovery for neurodevelopmental and neurodegenerative disorders, will release its financial results for Q2 and the first half of 2022 on August 15, 2022. The company will host an investor conference call at 4:30 PM ET on the same day, featuring updates from key executives, including the CEO and CFO. The event will provide insights into the company’s business, scientific, and financial progress. Questions from investors will be taken in advance.
FAQ
What is the market cap of Vyant Bio (VYNT)?
What does Vyant Bio, Inc. specialize in?
Who is the CEO of Vyant Bio, Inc.?
What are the recent achievements of Vyant Bio, Inc.?
What are some of Vyant Bio's key projects?
How can I get the latest updates about Vyant Bio, Inc.?
What is Vyant Bio's approach to financial sustainability?
Does Vyant Bio, Inc. engage in partnerships?
Where can I find investor information about Vyant Bio, Inc.?
What is the significance of Vyant Bio's therapeutic platforms?
How does Vyant Bio integrate data science into its operations?
